273 related articles for article (PubMed ID: 27125787)
1. Reslizumab: First Global Approval.
Markham A
Drugs; 2016 May; 76(8):907-11. PubMed ID: 27125787
[TBL] [Abstract][Full Text] [Related]
2. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
3. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
[TBL] [Abstract][Full Text] [Related]
4. Ixekizumab: First Global Approval.
Markham A
Drugs; 2016 May; 76(8):901-5. PubMed ID: 27098317
[TBL] [Abstract][Full Text] [Related]
5. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
Castro M; Mathur S; Hargreave F; Boulet LP; Xie F; Young J; Wilkins HJ; Henkel T; Nair P;
Am J Respir Crit Care Med; 2011 Nov; 184(10):1125-32. PubMed ID: 21852542
[TBL] [Abstract][Full Text] [Related]
6. Reslizumab: Maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.
Paton DM
Drugs Today (Barc); 2016 Jun; 52(6):323-9. PubMed ID: 27458609
[TBL] [Abstract][Full Text] [Related]
7. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
Máspero J
Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
[TBL] [Abstract][Full Text] [Related]
8. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.
Murphy K; Jacobs J; Bjermer L; Fahrenholz JM; Shalit Y; Garin M; Zangrilli J; Castro M
J Allergy Clin Immunol Pract; 2017; 5(6):1572-1581.e3. PubMed ID: 29122156
[TBL] [Abstract][Full Text] [Related]
9. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
Brusselle G; Germinaro M; Weiss S; Zangrilli J
Pulm Pharmacol Ther; 2017 Apr; 43():39-45. PubMed ID: 28159511
[TBL] [Abstract][Full Text] [Related]
10. Benralizumab: First Global Approval.
Markham A
Drugs; 2018 Mar; 78(4):505-511. PubMed ID: 29464664
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
12. Update on reslizumab for eosinophilic asthma.
Cardet JC; Israel E
Expert Opin Biol Ther; 2015; 15(10):1531-9. PubMed ID: 26372797
[TBL] [Abstract][Full Text] [Related]
13. Reslizumab in Eosinophilic Asthma: A Review.
Deeks ED; Brusselle G
Drugs; 2017 May; 77(7):777-784. PubMed ID: 28421429
[TBL] [Abstract][Full Text] [Related]
14. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
15. Benralizumab for the treatment of asthma.
Saco TV; Pepper AN; Lockey RF
Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab for the treatment of severe eosinophilic asthma.
Poulakos MN; Cargill SM; Waineo MF; Wolford AL
Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
18. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
19. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy.
Bakakos A; Rovina N; Bakakos P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921360
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
Lim HF; Nair P
Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
